Highlights of This Issue 5145

SPECIAL FEATURES

CCR Translations

5147  Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!  
Maria G. Castro, Gregory J. Baker, and Pedro R. Lowenstein  
See related article, p. 5290

CCR New Strategies

5150  New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances  
Joyce Liu and Ursula A. Matulonis

Molecular Pathways

5157  Molecular Pathways: Myeloid Complicity in Cancer  
Ingunn M. Stromnes, Philip D. Greenberg, and Sunil R. Hingorani

CCR Focus

5172  The Lymphoma Medicine Cabinet  
Susan E. Bates

5173  Putting the Clinical and Biological Heterogeneity of Non-Hodgkin Lymphoma into Context  
Owen A. O’Connor and Kensei Tobinai

5182  Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype  
Kieron Dunleavy, Mark Roschewski, and Wyndham H. Wilson

5194  New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?  
Martin Dreyling, Simone Ferrero, Niklas Vogt, and Wolfram Klapler on behalf of the European Mantle Cell Lymphoma Network

CANCER THERAPY: CLINICAL

5255  A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies  
Timothy S. Parmee, King Lee, John Luddy, Claudia Maturo, Robert Rodriguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David Hurd, Leslie R. Ellis, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, and Bayard L. Powell

PERSONALIZED MEDICINE AND IMAGING

5265  Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer  
Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteve, Rony Avritscher, Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi, Christos Hatzis, and W. Fraser Symmans
CANCER THERAPY: PRECLINICAL

5290 Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright, Alan L. Chang, Mahua Dey, Irina V. Balyasnikova, Chung Kwon Kim, Alex Tobias, Yu Cheng, Julius W. Kim, Jian Qiao, Lingjiao Zhang, Yu Han, and Maciej S. Lesniak
See related commentary, p. 5147

BIOLOGY OF HUMAN TUMORS

5302 Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics
Jing Xia, Bruce J. Trock, Roman Gulati, Leslie Mallinger, Matthew R. Cooperberg, Peter R. Carroll, H. Ballentine Carter, and Ruth Etzioni
ABOUT THE COVER

The cover shows the expression of long noncoding RNAs in normal and malignant bladder urothelium as detected by microarray. Unsupervised hierarchical clustering reveals discrimination of normal, low-grade and high-grade malignant tissues. For details, see the article by Peter and colleagues on page 3311 of this issue.